Boston, MA -- (SBWIRE) -- 01/03/2014 -- Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Bexsero (Meningococcal group B vaccine, rDNA, 4-component, adsorbed) is the brand name for Novartis' four-component meningococcal vaccine that is indicated to protect children, adolescents, and adults two months of age and older against invasive infection caused by N. meningitidis serogroup B. Bexsero received EMA approval in January 2013 and is the first serogroup B vaccine to be marketed in the 5EU (EMA, 2012).

View Full Report Details and Table of Contents

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Bexsero including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Bexsero for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to Get This Report

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Bexsero performance
- Obtain sales forecast for Bexsero from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- PharmaPoint: Meningococcal Vaccines - Australia Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Spain Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Meningococcal Vaccines - Brazil Drug Forecast and Market Analysis to 2022
- Travel Vaccines Market to 2019 - Hepatitis A, Japanese Encephalitis and Meningococcal Vaccine Segments to Drive Growth
- Menomune (Meningococcal Vaccines) - Forecast and Market Analysis to 2022